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Abstract
Left ventricular noncompaction (LVNC) is accepted as an unclassified (the American 
Heart Association) or a genetic cardiomyopathy (the European Society of Cardiology), 
but some argue that this phenotype may be a morphologic trait shared by different 
cardiomyopathies. This chapter covers the state of the art on the pathology, underly-
ing mechanisms, its clinical manifestations, and diagnosis and treatment modalities of 
LVNC. LVNC may be defined as follows: an inner non‐compacted layer with prominent 
left ventricular trabeculae and deep intertrabecular recesses and a thin outer compacted 
layer. Mechanisms are still debatable, with the hypothesis of compaction arrest during 
embryogenesis as the most accepted theory. Genetic data support LVNC as a distinct 
cardiomyopathy, although evidence for LVNC as a shared morphological trait is not 
ruled out, since LVNC may be associated with other cardiomyopathies, congenital heart 
diseases and in some cases may be acquired. Diagnosis is based on imaging and may be 
confirmed by the use of genetics. Clinical picture and prognosis and the management 
options are discussed.
Keywords: cardiomyopathy, Noncompaction, Echocardiography, cardiovascular 
magnetic resonance, prognosis
1. Introduction
Left ventricular noncompaction (LVNC) is a myocardial disorder that has been thought to 
occur due to the failure of left ventricle (LV) compaction during embryogenesis, leading to 
distinct morphological characteristics in the ventricular chamber [1]. In its first description, 
about 80 years ago, LVNC occurred in association with complex congenital heart diseases. 
More recently, an isolated form of LVNC was described [2], followed by many other reports. 
The involvement of the right ventricle in the noncompaction process has been increasingly 
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identified, and the condition is now included among the cardiomyopathies, but currently 
there is an intense debate whether LVNC is a distinct entity or a trait common to several car-
diac conditions [3].
2. Anatomy and pathology
Left ventricular noncompaction (LVNC) is defined by essential markers: an inner noncom-
pacted layer with prominent left ventricular (LV) trabeculae and deep intertrabecular recesses, 
and a thin compacted layer. There is a spectrum of morphologic variability, ranging from 
hearts with different degrees of noncompaction extension and amount, and right ventricular 
involvement.
From hearts obtained from autopsies or transplantation, LVNC diagnosis is based on the 
presence of a two‐layered ventricular wall, comprising a thinner compact epicardial layer 
and an inner noncompacted layer, with prominent trabeculations associated with deep, inter-
trabecular recesses that communicate with the ventricular cavity but not with the coronary 
circulation [2, 3].
Noncompacted areas are commonly located at the LV apex and mid‐apical wall segments, 
but typically spares the interventricular septum. When associated with hypertrophic car-
diomyopathy phenotype (HCM), the hypertrophied septum coexists with the LVNC pheno-
type. Other described associations include dilated cardiomyopathy (DCM) and, more rarely, 
restrictive cardiomyopathy (RCM) or arrhythmogenic right ventricular cardiomyopathy 
(ARVC). Besides the relationship of LVNC with other cardiomyopathies, which may share 
the same genetic basis, there has been considerable controversy regarding the differentiation 
from normal LV trabeculation, which seems to occur in some normal asymptomatic individu-
als as found in analysis from the MESA study [4].
Histopathology has shown continuity between the endothelium of inter‐trabecular recesses 
and that of the endocardium, distinguishing LVNC from persistent sinusoids. Other findings 
have included loosely organised myocytes and endocardial and subendocardial replacement 
fibrosis suggestive of ischaemic necrosis, which has been demonstrated by imaging tech-
niques in vivo [5].
LV dilatation and ischemia are frequently present, and thrombus formation in the recesses 
may occur, which may be associated with possible thromboembolic events.
3. Aetiology and mechanisms
There are several etiologic hypotheses for LVNC. It may occur as an isolated disease (iso-
lated LVNC) or in association with genetic diseases and congenital defects, as observed more 
commonly in infancy. The condition may also be sporadic and acquired, in physiological or 
pathologic conditions, and may also be permanent or transient. Thus, LVNC can originate 
during embryonic development or be acquired later in life.
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The theory that supports the embryogenic hypothesis has been based in observational foetal 
studies showing the coexistence of LVNC with heart block and congenital heart diseases and 
from experimental studies on LVNC [6]. In humans, the embryonic myocardium is composed 
of a loose meshwork of interwoven fibres separated by deep recesses, which communicate 
with the LV cavity, allowing an increase in the myocardial surface area and the exchange 
diffusion from the cavity. From the 5th–8th weeks of embryogenesis, LV trabecular compac-
tion occurs simultaneously with the invasion of the myocardium by the coronary vasculature 
coming from the epicardium. The LV compaction progresses from the heart base to the apex 
and from the epicardium to the endocardium [1]. LVNC is thus thought to result from the 
arrest of trabecular compaction during this phase of embryogenesis. A second embryogenic 
hypothesis suggests that LVNC results from the inhibition of the regression of embryonic 
structures that would maintain the looseness of cells or of cell bundles [7].
On the other hand, evidence supports the hypothesis that the pathogenetic mechanisms lead-
ing to noncompaction may occur in adult life, ending in acquired forms of LVNC and support-
ing a non‐embryogenic theory. This is the case of young athletes, pregnant women, patients 
with sickle cell disease, and renal failure, which may present the phenotype of LVNC. In 
athletes, the phenotype seems to relate to intensive training, but in a small proportion of 0.9% 
has been found to develop ultimately LV dysfunction suggestive of a LVNC cardiomyopathy 
[8]. In pregnancy, an important proportion of women, described as up to 25% were found to 
develop LVNC phenotype de novo, which was reversible. This pattern was not shown to be 
associated with deleterious clinical events and has been proposed to result from a response to 
increased loading conditions [9]. Also, in sickle cell disease, this pattern has been found and 
hypothesised to result from chronic anaemia and increased preload, resulting in a stimulus 
for hypertrabeculation [10].
4. Genetics
The LVNC trait may be familial, inherited, or non‐familial, sporadic. Non‐familial forms are 
diagnosed when LVNC is proven absent in relatives. As presented above, sporadic LVNC can 
be acquired and may be transient, as in highly trained athletes, sickle cell anaemia patients, 
and pregnancy. Many familial cases identified to date are associated with mutations in the 
same genes that cause other types of cardiomyopathies but may also occur isolated.
In fact, several studies suggest that noncompaction of the LV myocardium is a genetically 
heterogeneous disorder [11], with a familial and a sporadic form. Studies of the familial 
form have shown that LVNC may be transmitted as an autosomal dominant inheritance with 
incomplete penetrance, as an autosomal recessive, and as X‐linked traits. Sporadic cases of 
LVNC and de novo mutations have also been recognised. To date, several disease loci have 
been identified.
The Barth syndrome was the first recognised genetic LVNC, characterised by dilated cardio-
myopathy associated with LVNC. It is an X‐linked disease with mutations in the G4.5 gene, 




functions in the mitochondria. This mutation was also identified in an X‐linked severe neona-
tal LVNC, allelic with the Barth syndrome.
Another mutation, located in the α‐dystrobrevin gene, was identified subsequently in patients 
with LVNC and associated with congenital heart diseases. [12]; α‐dystrobrevin is a cytoskel-
etal protein component of the dystrophin associated glycoprotein complex, which links the 
extracellular matrix to the dystrophin cytoskeleton of the muscle fibre. This mutation was 
associated with a significant phenotypic variability with variable severity.
Mutations in the Z‐line protein Cypher/ZASP have been identified in association with LVNC 
and dilated cardiomyopathy. This protein appears to play an important role in the mainte-
nance of the normal myocyte architecture of cardiac and skeletal muscle.
Another LVNC phenotype has been reported in association with a mutation in the Lamin A/C 
protein, which has been linked to dilated cardiomyopathy, conduction system diseases, and 
muscular dystrophy.
Recently, LVNC has been linked to sarcomere gene mutations, causing hypertrophic cardio-
myopathy. In a study of 247 families with cardiomyopathy, a mutation in the α‐cardiac actin 
gene, essential for cell maintenance, was associated with LVNC, apical hypertrophic cardio-
myopathy, and septal defects. Moreover, in a large study of patients with phenotype of LVNC, 
nine heterozygous mutations were identified in a proportion of the probands in genes encod-
ing α‐myosin heavy chain (MYH7), β‐cardiac actin (ACTC), and cardiac troponin T (TNNT2), 
with 100% penetrance in the family members [13]. Another study identified a mutation in 
the sarcomeric TPM1 gene, at 15q22.1, in a family with LVNC and a history of sudden death.
Some studies have suggested that the phenotype for isolated LVNC may appear during adult 
life in patients with muscular dystrophy and with myocarditis. Nevertheless, these cases were 
not followed serially clinically and with an imaging modality, and the significance of the LV 
hypertrabeculation described is still unclear.
Although, many genes associated with LVNC are associated with additional phenotypes, 
like hypertrophic or dilated cardiomyopathies or congenital heart defects, several mutations 
were described in association with isolated LVNC. For instance, mutations in gene MIB1 were 
identified in two families with LVNC and autosomal dominant inheritance [14]. Recently, an 
important role in trabeculation for endocardial expression of a Notch ligand, Fkbp1a, was 
reported, [15] which was confirmed in a mouse model, suggesting its direct involvement in 
the LVNC phenotype.
A large number of genes have been identified in relation with the LVNC phenotype in asso-
ciation with other cardiomyopathies, congenital and acquired heart diseases, as well as part 
of syndromes; specific genetic mutations have been related with the LVNC phenotype, and 
there is a need for large databases and systematic follow‐up with clinical and imaging to 
obtain definite conclusions on the clinical and prognostic significance of LVNC phenotype in 
relation with the genotype.
The role of modifying genes or epigenetics and load changes may influence the relationship 
of genotype‐phenotype and contribute to explain the phenotype variability.
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5. Epidemiology
LVNC has been considered rare, and its incidence and prevalence are uncertain, but is com-
monly diagnosed, due to increased awareness and more accurate imaging methods.
LVNC has been described to occur in infants (0.81 per 100,000 infants/year), children (0.12 
cases per 100,000 children/year), and adults (prevalence suggested as 0.014% of patients 
referred for echocardiography and 0.05% among all adult echocardiograms in a large institu-
tion) [16, 17]. In a large population of patients with LV ejection fraction <45%, the prevalence 
was 3.7% [18]. However, LVNC can occur as an isolated myocardial trait or be associated 
with cardiomyopathies (hypertrophic, restrictive, dilated, and arrhythmogenic), congenital 
heart diseases, and complex syndromes affecting multiple organs and tissues, including mito-
chondrial diseases caused by mutations in both nuclear and mitochondrial genes, leading to 
increased uncertainty on the prevalence.
In fact, given the variability of clinical presentation, the prevalence of LVNC is largely 
unknown.
6. Clinical manifestations
Heart failure, ventricular and atrial arrhythmias, and systemic embolic events comprise the 
typical complications in patients with LVNC and may occur at any age. However, the initial 
presentation is variable and the patient may be asymptomatic (frequently diagnosed during a 
family screening) or present any of the clinical features and complications, including sudden 
death.
In its severe neonatal form, LVNC may manifest as heart failure or ventricular arrhythmias, 
which may lead to sudden death [2]. Studies of older children and adults have reported a 
high incidence of severe manifestations [7, 17, 19–22] such as LV dysfunction, thromboem-
bolic events, which probably originate in the deep intertrabecular recesses, arrhythmias, and 
sudden death. Other studies, however, have found a much lower incidence of complications, 
suggesting subclinical or milder cases [23]. Table 1 presents clinical findings from published 
studies.
There is no agreement so far on the natural history and outcomes in LVNC because most stud-
ies are retrospective, populations are limited and use distinct study methods.
Heart failure seems to occur frequently, as over 50% of symptomatic patients, and most 
researchers also report ventricular arrhythmias, cardiovascular deaths, and sudden cardiac 
death. A recent registry of a large population of adult patients with LVNC found heart fail-
ure in 74%, LV systolic dysfunction in 88%, strokes in 10%, and syncope episodes in 9%, [20] 
suggesting the need for long term surveillance of LVNC patients. Other series have found a 
more benign prognosis [23]. A recent published series describe a mean freedom from death or 




Predictors of death and heart transplantation have been difficult to assess due to the variabil-
ity of the phenotype and the variable underlying pathophysiological scenarios. However, the 
presence of heart failure, history of sustained ventricular tachycardia or systemic thromboem-
bolism seem to be associated with an unfavourable prognosis among other phenotypes with 
distinct outcomes [21, 22]. In a recent study, mortality did not differ significantly between 
patients with isolated LVNC and control patients with dilated cardiomyopathy, [24] suggest-
ing that LV dysfunction rather than the phenotype itself is the risk‐increasing mechanism. 
However, this finding has not been confirmed by others [17].
7. Diagnosis
Cardiac imaging is essential for establishing the diagnosis of LVNC, not only to detect the 
characteristic features and application of the diagnostic criteria, but to assess the systolic and 
diastolic function, valve regurgitation, pulmonary hypertension, the presence of thrombus 
in the ventricular recesses. However, there is still a lack of agreement from the medical com-
munity regarding the best technique and the most reliable diagnostic criterion. Table 2 sum-
marises the most frequently used imaging criteria for LVNC diagnosis.
7.1. Echocardiography
Cardiac ultrasound is a first‐line technique for diagnosing LVNC, since it is a bedside modal-
ity, uses no radiation and is readily available. This modality allows the detection, location, 
Author Chin Ichida Oechslin Murphy Lofiego Aras Stanton Greutmann
Patients (N) 8 27 34 45 65 67 30 132
Population Paediatric Paediatric Adult Adult Adult Adult Adult >14 years‐old
Follow‐up ≤5 years ≤17 years 44 months 46 months 46 months 30 months 2.5 years 2.7 years
Family history 
(%)
50 44 18 51 31 33 – 23
Embolic events 
(%)




38 0 41 20 6 36 27 4
Heart failure
(%)
63 30 68 67 34 34 – 13
CV death or 
transplantation 
(%)
0 11 47 2 24 15 10 23
Sudden death 
(%)
13 0 18 2 5 9 10 9
LVNC, left ventricle noncowmpaction; CV, cardiovascular.
Table 1. LVNC clinical characteristics and outcomes.
Cardiomyopathies - Types and Treatments64
and confirmation of this condition. The first criterion was proposed by Chin et al. [2], who 
recommended the assessment of the ratio of X/Y dimensions in diastole—where X is the dis-
tance from the epicardial surface to the trough of the trabecular recesses, and Y the distance 
from the epicardial surface to the peak of the trabeculation. An X/Y ratio of up to 0.5 would be 
required for the diagnosis. The more widely used criterion, however, was proposed by Jenni 
et al. in which the ratio of noncompacted and compacted myocardium, measured from end 
systolic short‐axis images. If the ratio is >2, the criterion for LVNC is considered fulfilled [25] 
(Figures 1 and 2). Additionally, observation and quantification of the apical trabeculations are 
available by echocardiography, although sometimes challenging, and permit the use of the 
LVNC criterion proposed by Stöllberger et al. [26].
The inherent limitation of echocardiography in evaluating the LV apex and, often, other 
LV walls poses a diagnostic issue. If the image quality is poor, LVNC can be confused with 
apical cardiomyopathy, thrombus or fibroelastosis. The use of contrast echocardiography, 
which permits the visualisation of the trabeculations and the recesses that communicate with 
the cavity, may help in clarifying the diagnosis [27]. Additional information with prognos-
tic impact may be derived from the evaluation of LV systolic and diastolic function, mitral 
regurgitation, pulmonary hypertension. Systolic dysfunction is frequently present in LVNC. 
It has been hypothesised that microvascular disease with impaired coronary flow reserve and 
myocardial necrosis, as well as a primary myocardial disease, is responsible for the functional 
abnormalities [5], although in other cases a DCM may be associated, The presence of throm-
bus in the ventricular recesses, although rare, has been described.
More recently, speckle tracking has revealed abnormal LV rotation and twist, and these find-
ings are promising for diagnosis even in patients with normal ejection fraction [28]. Three‐
dimension echocardiography has been proposed as an alternative for detecting LVNC due to 
Jenni et al. [25] Stlöberger et al. [26] Petersen et al. [30] Jacquier et al. [31]
Echo Echo CMR CMR
‐ Ratio noncompacted/
compacted >2.0
‐ Three trabeculations 
protruding from the 
LV wall, apically to the 
papillary muscles, visible 
in one image plane
‐ Ratio noncompacted/
compacted >2.3
‐ Trabecular LV mass >20% of 
global LV mass,
‐ Intratrabecular recesses 
filled by blood flow from 
the LV cavity
‐ Intertrabecular spaces 
perfused from the 
ventricular cavity on 
colour Doppler imaging
‐ Acquisition: long‐axis 
end‐diastolic images
‐ Acquisition: end‐diastolic images
‐ Acquisition: short‐axis; 
end‐systolic images
‐ Trabeculations with 
the same echogenicity 
as the myocardium and 
synchronous with LV
‐ Acquisition: oblique 
views to differentiate false 
chords, aberrant bands, 
trabeculations
LV, left ventricle.




the lower dependence on the observer for image acquisition and higher reproducibility [29]. 
However, the image quality and resolution may be compromised in comparison with the 
conventional 2D, remaining uncertain its real value.
7.2. Cardiovascular magnetic resonance (CMR)
CMR is a non‐ionising high‐resolution technique without acoustic limitations, which reveals 
a wider extent of disease, particularly at the LV apex and the poorly observed segments, 
which are often problematic with echocardiography.
This modality confirms the presence of the anatomic features of LVNC, as well as an accu-
rate and reproducible measurement of the noncompacted and compacted myocardial layers 
(Figures 3 and 4). The diagnosis is supported if the end‐diastolic thickness of the noncom-
pacted layer is ≥2.3 times the compacted one, as proposed by Petersen et al. [30]. This criterion 
yielded >43% of positive subjects in MESA study, although this population included only 
asymptomatic individuals, with low pretest probability of disease [4].
CMR confirmation of trabeculated LV mass >20% of global LV mass fulfils the criterion pro-
posed by Jacquier et al. [31] although the feasibility and reproducibility of this methodology 
have been debated.
Figure 1. A systolic short‐axis image from an echocardiogram of a 27‐year‐old patient with LVNC, showing the ratio 
measurement of compacted layer (blue line) to noncompacted layer (red line) of >2; Doppler colour shows the blood 
flow in the recesses.
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Figure 2. A diastolic four‐chamber image from an echocardiogram of a patient with LVNC. Blue arrow—compacted 
layer; red arrow—noncompacted layer.
Figure 3. A diastolic four‐chamber view from a magnetic resonance cine study of a 23‐year‐old patient with LVNC, 




Fractal analysis was also used to quantify LV trabeculae. In a study of 30 patients of Captur 
et al., the combination of end‐diastolic measurements at basal, mid, and apical segments was 
found to be the best selector of LVNC cases from the normal population [32].
The combined use of echocardiography and CMR may contribute to lessening the risk of 
over diagnosing LVNC, which can occur with the isolated use of ultrasound, and overcome 
the limitations on reproducibility of echocardiography [33], but such an approach has not yet 
been validated.
Reliable evaluation of LV function is an additional advantage offered by CMR. Involvement of 
the right ventricle remains controversial because echocardiography presents inherent difficul-
ties in analysing this chamber, but CMR has been increasingly detecting biventricular LVNC, 
although no specific criteria have been proposed so far.
Late gadolinium enhancement (LGE) CMR, as a surrogate marker of fibrosis, has been detected 
in patients with LVNC and confirmed by histology. A recent study suggests that the pres-
ence and amount of LGE is associated with more severe clinical [34]. Abnormal T2‐weighting 
myocardial intensity and perfusion defects have been described as additional information 
obtained from CMR but its usefulness is not established so far.
7.3. Cardiac computed tomography
This modality has been proposed as an alternative to patients that have acoustic limitations 
to echocardiography and contra‐indications for CMR, due to the high spatial resolution pro-
vided by this technique [35].
Figure 4. A diastolic two-chamber view from a magnetic resonance cine study of a patient with LVNC and arrhythmia. 
Blue arrow—compacted layer; red arrows—noncompacted layer.
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7.4. Electrocardiogram
Electrocardiogram (ECG) may be normal. ECG changes, when present, are non‐specific and 
include LV hypertrophy and repolarisation abnormalities. Left bundle branch block is com-
mon, especially in patients with LV dysfunction. Wolff–Parkinson–White has been frequently 
detected in paediatric patients [36].
8. Management and prognosis
The true significance of noncompaction still remains a matter of debate, due to the genetic 
heterogeneity, the overlapping phenotype with other cardiomyopathies sharing the same 
genetic background, the high prevalence in neuromuscular diseases. These findings suggest 
that other factors may play a role in the development of LVNC disease [37]. Another impor-
tant challenge is the clear differentiation of the LVNC phenotype from the normal heart, since 
this is associated with the risk of overdiagnosis.
There are no specific guidelines for management of LVNC since evidence supporting the 
management is limited. First of all, management includes confirmation of the diagnosis by 
echocardiography or CMR.
Guidelines suggest that familial LVNC should be diagnosed by echocardiographic screening of 
family members [38]. Echocardiographic screening is recommended for family members, given 
that the symptoms are variable and the risks include heart failure and sudden cardiac death.
According to current guidelines, mutation‐specific genetic testing is recommended for family 
members and appropriate relatives, following the identification of an LVNC causative muta-
tion in the index case. Moreover, this testing may be useful for patients where the cardiolo-
gist has established a clinical diagnosis of LV noncompaction based on examination of the 
patient’s clinical manifestations (namely with increased pre‐test probability or left ventricular 
dysfunction [39]) and family history, electrocardiographic and echocardiographic phenotype 
or when associated with another cardiomyopathy or congenital heart disease. Following 
genetic and imaging assessment, the possibility of an early diagnosis of LVNC increases, 
ensuring appropriate monitoring and prophylactic measures.
According to recent American Heart Association/American College of Cardiology Scientific 
Statement on Eligibility and Disqualification Recommendations for Competitive Athletes 
With Cardiovascular Abnormalities, “until more clinical information is available, participa-
tion in competitive sports may be considered for asymptomatic patients with a diagnosis 
of LVNC and normal systolic function, without important ventricular tachyarrhythmias on 
ambulatory monitoring or exercise testing, and specifically with no prior history of unex-
plained syncope (Class IIb; Level of Evidence C)” [40].
The main therapeutic objectives are the prevention and treatment of complications, using con-
ventional measures. Thromboembolism, heart failure, and arrhythmias constitute the typical 
clinical features of LVNC to be addressed.
Anticoagulation for prevention of thromboembolism is probably only indicated in cases of LV 




to date no data are available to support these options. For symptomatic ventricular arrhyth-
mias, particularly the ones associated with LV and for heart failure, the treatment should 
follow current guidelines. In patients with severe LV dysfunction, ICD implantation and CRT 
therapy are measures to improve heart failure and prevent sudden death. In some cases, heart 
transplantation may be the option for patients with refractory heart failure [41].
9. Conclusion
The pathogenesis and diagnosis of LVNC remains a challenge. The disease may be second-
ary to genetic mutations that induce the myocardial pathology. However, phenotypes are 
heterogeneous, are frequently shared with other cardiomyopathy, suggesting the influence of 
additional modifiers or a common aetiology.
The detection of new genetic mutations and the evaluation of its relationship with phenotypes 
may shed light on the pathogenesis of this condition, which may have an impact on follow‐up 
and management.
The current awareness of the disease and the availability of high‐resolution imaging, namely 
CMR, have increased the number of diagnosed patients. There is, however, a risk of overdiag-
noses. The genotype and phenotype heterogeneity suggests the need for multicentre studies 
involving large populations, allowing more
robust conclusions regarding all the important areas of LVNC including the clinical ground, 
genetics, pathogenesis, diagnosis, and management.
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